问题 › 成本上涨快于价格 › HealthTech与数字健康
数字健康的成本挤压既是结果导向合同设计问题，也是定价问题。 对于数字健康公司，这体现在特定位置。承载答案的数字是风险收入份额和参与率，而这个行业特有的复杂性是，结果风险签约速度快于公司能否承担它的学习速度——12个月测量窗口对11个月销售周期。这个问题的通用版本和你实际面对的版本，第一步行动不同。
数字健康的成本挤压既是结果导向合同设计问题，也是定价问题。 对于数字健康公司，这体现在特定位置。承载答案的数字是风险收入份额和参与率，而这个行业特有的复杂性是，结果风险签约速度快于公司能否承担它的学习速度——12个月测量窗口对11个月销售周期。这个问题的通用版本和你实际面对的版本，第一步行动不同。
当风险份额上涨快于PMPM时，立即反应是削减参与成本。这值得做且有限：你只能移除一次成本，而测量窗口继续。
持久的回应是结构性的。结果归因前的更短合同期限。与参与率挂钩而非所有logo的续约重定价。改变捆绑内容，使价格调整落在付款方不直接比较的归因结果上。
另一半是组合。在大多数数字健康业务中，挤压不均匀——有些合同轻松传递风险份额，有些不能——将量移向第一组通常快于在第二组赢得价格争论。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 毛利率下降而注册会员保持
✓ 风险份额要求每次续约谈判
✓ 合同没有与参与率挂钩的机制
通常会让情况更糟的做法。 吸收更高的风险份额以保护logo流失，这训练付款方期望它，并使最终修正更大。
It is for you if you run or finance a digital health company and gross margin is falling while volumes hold. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Pricing Strategy · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 成本与利润率改善, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
将它们与外部可验证的事物挂钩，并给予通知。归因于公布指数的上涨是事实；归因于你成本的相同上涨是谈判邀请。
在存在可信指数的地方，它消除了年度争论，通常在第一个周期内收回成本。工作是选择客户接受为中性的指数。
那么杠杆在续约时，期间工作是组合和服务成本。这也是修复合同的时刻，因为同样的挤压会再次发生。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית